CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) with MMAE, targeting folate receptor (FRalpha) and TRPV6. It exhibits high binding affinity to FRalpha and low affinity to TRPV6. CBP-1008 shows antitumor activity and can be utilized for research in advanced solid tumors such as colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma, and follicular dendritic cell sarcoma.
Target:
TRP/TRPV Channel
* VAT and and shipping costs not included. Errors and price changes excepted
